Concepedia
Statistics
Publications
4
Citations
380
H-Index
Active since
2008
Affiliations
University of Colorado Denver(Current)
The University of Texas MD Anderson Cancer Center
Array BioPharma (United States)
Sarah Cannon
South Texas Accelerated Research Therapeutics
Renae Chavira is an author at University of Colorado Denver specializing in pharmacology, cancer pharmacology, and oncology.
Publications per year
2008–2018
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Stacy L. Moulder, Virginia F. Borges, Tara Baetz et al. · Clinical Cancer Research · 2017 · 160 citations
Medicine, Oncology, Pharmacology +16
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C. Bendell, Milind Javle, Tanios Bekaii‐Saab et al. · British Journal of Cancer · 2017 · 133 citations · Full text
Medicine, Oncology, Pharmacology +15
Clinical trial: single‐ and multiple‐dose pharmacokinetics of polyethylene glycol (PEG‐3350) in healthy young and elderly subjects
Russell W. Pelham, Laura C. Nix, Renae Chavira et al. · Alimentary Pharmacology & Therapeutics · 2008 · 56 citations
Pharmacy, Pharmacokinetics, Pharmacology +16
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
Richard S. Finn, Daniel H. Ahn, Milind Javle et al. · Investigational New Drugs · 2018 · 31 citations
Medicine, Oncology, Pharmacology +13
1–4 of 4